Primary Gastric Melanoma: a Diagnostic Challenge

Aggarwal, Riti; Dhawan, Shashi; Chopra, Prem

doi:10.1007/s12029-013-9530-6

Cited by 8 publications

(6 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Search of the literature resulted in 599 articles. Twenty‐five case reports fulfilled our inclusion criteria and were included in this systematic review 1–4,16–36 . Figure 1 presents the trial flow of our study.…”

Section: Resultsmentioning

confidence: 99%

“…It mainly concerns adult population; its clinical manifestations are not specific and mimic the ones of gastric adenocarcinoma or lymphoma 2,3 . Differential diagnosis between PGM and metastatic gastric melanoma poses a challenge to clinicians and it relies on a histological diagnosis of melanoma in combination with the absence of a primary tumour in another site 4 …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Primary gastric melanoma in adult population: a systematic review of the literature

Schizas

Tomara

Katsaros

et al. 2020

ANZ Journal of Surgery

View full text Add to dashboard Cite

Background Primary gastric melanoma (PGM) is a rare malignant tumour of the stomach with poor prognosis. The aim of this systematic review was to assess the available literature on this entity and to highlight its biological behaviour and preferred treatment approach. Methods PubMed and Cochrane bibliographical databases were independently searched (last search: 2 February 2020) by two investigators for articles reporting on PGM in the adult population. Results Twenty‐five studies met the inclusion criteria and concerned collectively 25 patients (18 males and seven females) with an age of 63.4 ± 8.97 years (mean ± standard deviation). Main symptoms included abdominal pain (64%), weight loss (48%) and hematemesis or melena (32%). The most frequent tumour location was the body of the stomach (54.2%). All tumours were surgically resected and the majority of the patients had a partial gastrectomy (52%). Median recurrence time was 5 months and 12% of patients reached 5‐year survival landmark. Conclusion PGM is a rare disease characterized by an aggressive malignant behaviour. Its differential diagnosis from a metastatic lesion is crucial. A prompt diagnosis and therapeutic approach are needed. Further studies are required to elucidate the optimal management of this clinical entity.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Primary gastric melanoma in adult population: a systematic review of the literature

Schizas

Tomara

Katsaros

et al. 2020

ANZ Journal of Surgery

View full text Add to dashboard Cite

show abstract

“…Invasion and migration of malignant tumor cells is a complex multi-step and multi-factor process ( 46 , 47 ). Melanoma is highly malignant and prone to hematogenous and lymphatic metastasis with poor prognosis ( 1 ). Early detection and diagnosis are particularly important for the prediction of melanoma prognosis ( 4 ).…”

Section: Discussionmentioning

confidence: 99%

“…Melanoma originates from neural crest of epiblast and is a malignant melanoma originating from the pigmented areas of the skin (cutaneous melanoma elaborated in this study), mucosa, eye and the central nervous system (1,2). The pathogenesis of melanoma is still unclear.…”

Section: Introductionmentioning

confidence: 96%

Mechanisms of JAK‑STAT signaling pathway mediated by CXCL8 gene silencing on epithelial‑mesenchymal transition of human cutaneous melanoma cells

Yuan²,

2020

Oncol Lett

View full text Add to dashboard Cite

Effect of CXCL8 gene silencing-mediated JAK-STAT signaling pathway on epithelial-mesenchymal transition (EMT) of human cutaneous melanoma cells was explored. Eighty patients with cutaneous melanoma were enrolled in the study. Cells were transfected accordingly and divided into five groups: The blank group (human cutaneous melanoma cells), NC group (human cutaneous melanoma cells + blank vector plasmid transfection), CXCL8 siRNA group (human cutaneous melanoma cells + CXCL8 silent expression vector plasmid transfection), AG490 group (human cutaneous melanoma cells + JAK-STAT signal pathway inhibitor transfection), CXCL8 siRNA + AG490 group (human cutaneous melanoma cells + JAK-STAT signaling pathway inhibitor + CXCL8 silent expression vector plasmid transfection). The expression levels of CXCL8, JAK2, STAT3, epithelial cadherin (E-cadherin), neurotrophic cadherin (N-cadherin) and vimentin in tissues and cells were detected by RT-qPCR and western blot analysis. CCK-8 and flow cytometry were used to detect cell proliferation and apoptosis. Compared with adjacent normal tissues, the expression of E-cadherin in human cutaneous melanoma tissues was significantly decreased, whereas the expression of CXCL8, JAK2, STAT3, vimentin and N-cadherin was significantly increased (P<0.05). Compared with the blank group, CXCL8 siRNA group and CXCL8 siRNA + AG490 group had significantly lower expression of CXCL8 (P<0.05). Compared with the blank group, the expression levels of JAK2, STAT3, vimentin and N-cadherin in CXCL8 siRNA group, AG490 group and CXCL8 siRNA + AG490 group were decreased, the expression of E-cadherin was increased, the cell proliferation ability was decreased and apoptosis was increased (P<0.05). Compared with CXCL8 siRNA group, the expression of JAK2, STAT3, vimentin and N-cadherin in CXCL8 siRNA + AG490 group were significantly decreased, the expression of E-cadherin was significantly increased, cell proliferation ability was decreased and apoptosis was increased (P<0.05). In conclusion, CXCL8 gene expression silencing may inhibit EMT and cell proliferation while promoting cell apoptosis of human cutaneous melanoma cells by inhibiting the activation of JAK-STAT signaling pathway.

show abstract

“…Трудности предоперационной диагностики этой опухоли заключаются в том, что зачастую распределение меланина в ней бывает неравномерным, и врачу-эндоскописту сложно определить наиболее оптимальный участок для биопсии [8]. Биопсия выполняется, как правило, с края опухоли, во избежание кровотечения.…”

Section: Discussionunclassified